NASDAQ: NUVL
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted small molecule therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, the company develops innovative small molecules intended to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent's pipeline includes zidesamtinib, an investigational ROS1-selective inhibitor with an NDA under FDA review for TKI pre-treated ROS1-positive NSCLC; neladalkib, an investigational ALK-selective inhibitor with a recently submitted NDA for TKI pre-treated ALK-positive NSCLC; and NVL-330, a HER2-targeted candidate in Phase 1a/1b clinical trials for HER2-altered NSCLC. The company also has multiple discovery-stage research programs targeting additional kinase-driven cancers. Updated
Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session,…
Pre-Market Stock Futures: Futures are trading lower after the stock market tried to take a cue from Monday’s action, and things didn’t work out quite as well on Tuesday. Once again, the…
The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names…
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted small molecule therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
